Is Apogee Therapeutics, Inc. profitable?

Apogee Therapeutics, Inc. is not currently profitable: it reported a net loss of $274.6M over the trailing twelve months.

What is Apogee Therapeutics, Inc.'s earnings per share?

Apogee Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-4.33.

Where does Apogee Therapeutics, Inc.'s income statement data come from?

Every line is extracted from Apogee Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Apogee Therapeutics, Inc. APGE Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Research and development	$60.82M+31.1%	$58.44M-3.0%	$54.18M+18.5%	$55.7M+67.7%	$46.39M+61.5%
General and administrative	$21.95M+31.4%	$19.61M+25.3%	$17.1M+31.8%	$17.46M+60.0%	$16.71M+76.5%
Other operating expenses	$82.77M+31.2%	$78.06M+2.9%	$71.28M+21.5%	$73.17M+65.8%	$63.1M+65.3%
Total operating expenses	$82.77M+31.2%	$78.06M+2.9%	$71.28M+21.5%	$73.17M+65.8%	$63.1M+65.3%
Operating income	-$82.77M-31.2%	-$78.06M-2.9%	-$71.28M-21.5%	-$73.17M-65.8%	-$63.1M-65.3%
Interest income	$8.74M+11.5%	$8.73M+0.6%	$6.32M-34.7%	$7.14M-30.7%	$7.84M+28.8%
Other income (expense), net	$8.74M+11.5%	$8.73M+0.6%	$6.32M-34.7%	$7.14M-30.7%	$7.84M+28.8%
Income before income taxes	-$74.03M-34.0%	-$69.33M-3.2%	-$64.96M-32.5%	-$66.02M-95.2%	-$55.26M-72.2%
Income tax expense	$79K-4.8%	$62K+244%	$61K—	$72K—	$83K—
Net income	-$74.11M-33.9%	-$69.39M-3.2%	-$65.02M-32.6%	-$66.1M-95.5%	-$55.34M-72.4%
Diluted earnings per share	-$1.06-11.6%	-$1.03+13.4%	-$1.11-29.1%	-$1.13-88.3%	-$0.95-48.4%
Basic earnings per share	-$1.06-11.6%	-$1.03+13.4%	-$1.11-29.1%	-$1.13-88.3%	-$0.95-48.4%
Weighted-average shares, diluted	69.7M+19.7%	60.7M+10.0%	58.8M+3.5%	58.4M+3.4%	58.2M+16.0%
Weighted-average shares, basic	69.7M+19.7%	60.7M+10.0%	58.8M+3.5%	58.4M+3.4%	58.2M+16.0%
Other income, net (Note 6)	$8.74M+11.5%	$8.73M+0.6%	$6.32M-34.7%	$7.14M-30.7%	$7.84M+28.8%
EBIT	-$82.77M-31.2%	-$78.06M-2.9%	-$71.28M-21.5%	-$73.17M-65.8%	-$63.1M-65.3%
EBITDA	-$82.36M-31.0%	-$77.65M-2.4%	-$70.88M-20.9%	-$72.77M-65.1%	-$62.89M-64.8%
EBITDA	-$82.36M-31.0%	-$77.65M-2.4%	-$70.88M-20.9%	-$72.77M-65.1%	-$62.89M-64.8%
EBIT	-$82.77M-31.2%	-$78.06M-2.9%	-$71.28M-21.5%	-$73.17M-65.8%	-$63.1M-65.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Apogee Therapeutics, Inc. profitable?: Apogee Therapeutics, Inc. is not currently profitable: it reported a net loss of $274.6M over the trailing twelve months.
What is Apogee Therapeutics, Inc.'s earnings per share?: Apogee Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-4.33.
Where does Apogee Therapeutics, Inc.'s income statement data come from?: Every line is extracted from Apogee Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.